Microspheres for the treatment of a prostate hyperplasia by active embolization

• US 10,265,271 B2
• Filed: 05/16/2008
• Issued: 04/23/2019
• Est. Priority Date: 03/24/2000
• Status: Active Grant

• Current Assignee: Biosphere Medical Inc. (Merit Medical Systems, Inc.)
• Original Assignee: Biosphere Medical Inc. (Merit Medical Systems, Inc.)
• Inventors: Vogel, Jean-Marie, Boschetti, Egisto
• Primary Examiner(s): Kishore, Gollamudi
• Application Number:
  US12/122,590
• Publication Number:
  US 20080220077A1
• Time in Patent Office: 3,994 Days
• Field of Search: 424489, 424501
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y10T 428/2982 Particulate matter [e.g., sphere, flake, etc.]

Abstract

The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.

Claims

1. A method of reducing the blood supply to a prostate of a patient to treat a hyperplasia, comprising administering to the prostate of the patient biocompatible, hydrophilic and substantially spherical microspheres comprising

(i) an acrylamide, acrylate, or acrylic polymer or copolymer, and

(ii) a drug,

wherein the drug is associated with the polymer by an ionic interaction, and

wherein the diameter of the microspheres ranges from 10 μ

m to 2000 μ

m.

2. The method of claim 1, wherein said microspheres comprise a biocompatible sodium acrylate and vinyl alcohol copolymer.

3. The method of claim 1, wherein said microspheres appear smooth under magnification of up to 1000 times.

4. The method of claim 1, wherein the microspheres are swellable.

5. The method of claim 1, wherein the drug is selected from the group consisting of an antibiotic, a local anesthetic agent, and a hormone.

6. The method of claim 1, wherein the treatment is temporary.

7. The method of claim 1, wherein the treatment is permanent.

8. The method of claim 1, wherein the microspheres further comprise a polyvinyl alcohol.

9. The method of claim 1, wherein the microspheres further comprise a fluorescent marker, chemical dye, contrast agent, magnetic resonance imaging agent, or a mixture thereof.

10. The method of claim 9, wherein the contrast agent is a paramagnetic or superparamagnetic contrast agent, or a mixture thereof.

11. The method of claim 9, wherein the contrast agent is a barium salt, magnetite salt, iodine salt, iron oxide, or a mixture thereof.

12. The method of claim 1, wherein the microspheres further comprise an iron oxide.

13. A method of treating a benign hyperplasia in the prostate of a patient by embolization, said method comprising

administering to the prostate of the patient, biocompatible, hydrophilic and substantially spherical microspheres comprising an acrylamide polymer,

wherein the diameter of the microspheres ranges from 10 μ

m to 2000 μ

m.

14. The method of claim 13, wherein the microspheres further comprise gelatin.

15. The method of claim 13, wherein the microspheres further comprise a fluorescent marker, chemical dye, contrast agent, magnetic resonance imaging agent, or a mixture thereof.

16. The method of claim 15, wherein the contrast agent is a paramagnetic or superparamagnetic contrast agent, or a mixture thereof.

17. The method of claim 15, wherein the contrast agent is a barium salt, magnetite salt, iodine salt, iron oxide, or a mixture thereof.

18. The method of claim 13, wherein the microspheres further comprise an iron oxide.

19. A method of treating a benign hyperplasia in the prostate of a patient by embolization, said method comprising administering to the prostate of the patient, biocompatible and substantially spherical polymer microspheres, wherein the diameter of the microspheres ranges from 10 μ

m to 2000 μ

m.

20. The method of claim 19, wherein the microspheres comprise an acrylamide, acrylate, or acrylic polymer or copolymer.

21. The method of claim 19, wherein the microspheres comprise a sodium acrylate and vinyl alcohol copolymer.

22. The method of claim 19, wherein the microspheres are swellable.